Akcea and Ionis Announce Positive Phase 2 Clinical Trial Results

Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (IONS), announced positive topline clinical trial results on September 24. The Phase 2 clinical trial is studying the effect of AKCEA-APO(a)-LRx on patients with established cardiovascular disease and elevated levels of lipoprotein(a), known as Lp(a). The goal of the Phase 2 clinical study was to establish dosing amount and frequency for the Phase 3 outcomes study. The Phase 2 clinical trial showed that Akcea’s drug lowered Lp(a) while maintaining a favorable safety and tolerability profile.


Rocket Tickers sent an alert to subscribers at 7:00 am. The next trade took place at 8:12 am for $29. The stock price faded back at the market open to $28.13. Then, the stock price climbed to close at $33.08 with a 14% gain on the event day.

Visit the Knowledge Center for more information about clinical trials and how to trade them.

Check out our latest Live Webinar which provides more information about price patterns after clinical trial announcements and how to trade them.

Subscribe here if you would like to start receiving these signals in real-time and start trading!